CAMBRIDGE, Mass.--(BUSINESS WIRE)--Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an ...

CAMBRIDGE, Mass., March 28, 2026--(BUSINESS WIRE)--Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) ...

FLORENCE, Italy — During the 2025 European Congress of Internal Medicine, held from March 5 to 8, the scientific program featured a special session in collaboration with the European Society of ...

Anumana, a leader in cardiovascular AI, has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its pulmonary hypertension (PH) algorithm, an AI-enabled software-as-a-medical-device ...